Upcoming News
Seven finalists pitched their ventures live at the HolonIQ Back to School Summit in New York City. Media Contact: Jackie Jircitano, Catalyst @ Penn GSE Communicationsjackie@alessicommunication.com *Note for TV and
Do you say stutter or stammer? If you’ve ever wondered whether there’s a difference between these two words, you’re not alone. Parents searching for help often find themselves confused by varying terminology across websites, books, and even conversations with different professionals.
Here’s the simple truth: stutter and stammer describe the exact same speech condition. The difference isn’t medical or clinical—it’s geographical. Think of it like “elevator” versus “lift” or “apartment” versus “flat.” Same thing, different words, depending on where you are in the world.
The stutter vs stammer distinction is primarily about geography and linguistic tradition.
In the United States and Canada, “stutter” dominates. You’ll hear American speech therapists say, “Your child has a stutter,” and parents might search online for “stuttering therapy near me.” The Stuttering Foundation of America and National Stuttering Association use this term exclusively.
In the United Kingdom, Ireland, and many Commonwealth countries, “stammer” takes the lead. British families visit the NHS for “stammering assessments,” and organizations like the British Stammering Association (STAMMA) champion this terminology. In London, a parent would likely say, “My child has started stammering.”
Australia and New Zealand present an interesting mix, with both terms used interchangeably, though “stutter” has been gaining ground in professional settings.
In India and South Africa, you’ll hear both, often influenced by whether the speaker learned British or American English. Many professionals use the terms interchangeably within the same conversation.
This regional variation extends to everyday usage too. An American might say, “I stuttered during my presentation,” while a Brit would say, “I stammered through my speech.”
Despite the different terminology, medical and diagnostic manuals are clear: stammer vs stutter refers to the same neurological condition affecting speech fluency.
The World Health Organization’s ICD-11 lists it as “Developmental speech fluency disorder,” carefully avoiding regional preferences. The diagnostic code (6A01.0) remains identical whether your doctor writes “stuttering” or “stammering” in their notes.
The American Psychiatric Association’s DSM-5 calls it “Childhood-Onset Fluency Disorder,” with “stuttering” in parentheses. This reflects American terminology preferences while maintaining international clarity.
Whether you call it stuttering or stammering, the condition involves:
The underlying neurology remains identical regardless of the label. Brain imaging shows the same patterns in British “stammerers” and American “stutterers.”
Speech-language professionals worldwide have developed strategies for managing these terminology differences.
In Research and Academic Settings, “stuttering” has become the de facto international standard. Major journals like the Journal of Fluency Disorders primarily use “stuttering,” even when publishing British or Australian research. This standardization helps researchers communicate across borders.
PubMed, the world’s largest medical database, returns about 8,500 results for “stuttering” versus 2,100 for “stammering”—though many papers use both terms to ensure comprehensive searchability.
In Clinical Practice, professionals often adapt to their audience. A British-trained therapist working in New York might switch to saying “stuttering” with American families while maintaining “stammering” when calling colleagues in London.
Many international organizations now include both terms. The International Fluency Association uses “stuttering/stammering” in official documents, acknowledging both traditions.
The Lidcombe Program (from Australia), Camperdown Program (also Australian), and Speech Easy (American) work identically whether treating “stuttering” or “stammering.”
A child receiving “stammering therapy” in Manchester gets the same evidence-based techniques as one receiving “stuttering therapy” in Manhattan. The exercises, strategies, and outcomes remain consistent.
Understanding the stutter vs stammer non-difference helps in several practical ways.
If you work with children from diverse backgrounds, recognizing both terms prevents misunderstandings. A British parent emailing about their child’s “stammer” needs the same support as an American parent describing a “stutter.”
Whether your child stutters or stammers, whether you seek stuttering therapy or stammering support, the core truth remains: you’re addressing the same condition with the same proven interventions.
The stammer vs stutter debate is ultimately about language, not medicine. Like choosing between “grey” and “gray,” both spellings point to the same color—or in this case, the same speech pattern that affects millions worldwide.
What matters isn’t the word we use but the support we provide. A child who “stammers” in Edinburgh faces the same challenges as one who “stutters” in Atlanta. Both deserve understanding, evidence-based intervention, and the opportunity to communicate confidently.
Parents, don’t let terminology confusion delay seeking help. Whether you google “stuttering therapy” or “stammering treatment,” you’re looking for the same thing: support for your child’s communication journey. Visit Stutter Stars or browse our blog to learn more about evidence-based support options.
Professionals, embrace the linguistic diversity. Being fluent in both terminologies makes you a more effective, culturally competent clinician.

SAY IT Labs
Erich Reiter, Erich holds a M.Sc.in Speech and Communication Disorders from the Massachusetts General Hospital, and an M.Sc. in Computational Linguistics from the University of Buffalo. Erich started his career in 2004 working as a speech recognition engineer in the Silicon Valley for Nuance Communications, the original makers of SIRI. In 2012, after losing a friend to ALS, a new interest in technology for people with speech disorders emerged. Erich left Nuance in 2014 to become a speech and language pathologist.
In 2019, Erich co-founded SAY IT Labs where he combines his knowledge of artificial intelligence, speech recognition, and speech and language pathology to create video games for people with speech disorders.

Limbic AI
Nathaniel Rose is the Co-Founder of Lymbic AI and a neurotechnology researcher building novel authentication paradigms through brain-computer interfaces. During his graduate studies, Nathaniel’s previous research under Dr. Aldo Faisal at Imperial College London focused on immersive applications using gaze selection and non-invasive BCI for the control of open-sourced robotic platforms. He has over 10 years of software engineering experience having led development teams at Microsoft, Circle Pay & Ripple, provisioning distributed data platform infrastructure, automated ML operation pipelines, and web3 smart contract governance for the XRP ledger. Nathaniel and his team at Lymbic AI now pioneering brain signal biometric security to combat the growing cyberattacks and authentication exploits in the industry.

Neurolentech
Fiona Nielsen, CEO of Neurolentech – Serial entrepreneur in bioinformatics, genomics and big data. Previously at Illumina and Genomics England and o2h; Founder of DNAdigest and co-founder of Repositive.
In 2013 Fiona founded the charity DNAdigest promoting best practices for efficient and ethical data sharing for genomics research for the benefit of patients. She next founded the startup Repositive, a company that focused on sharing of genetic data and patient-derived cancer models for preclinical research. Fiona led Repositive for 7 years as CEO, partnering with 25+ biopharma and preclinical CROs worldwide creating a global marketplace for patient-derived preclinical cancer models. Fiona Nielsen has accumulated several accolades, among them Highly Commended for CEO of the year by Cambridge Independent Science and Technology Awards as well as WISE100 – Women in Social Enterprise. Fiona is a highly sought after speaker and mentor for companies in life sciences and technology. Fiona joined Neurolentech on a part-time basis from December 2022 and full-time from April 2023.

MindAhead
Nina Kiwit is a serial entrepreneur with a background in predictive modeling, design thinking, and digital health. She led and built two previous startups, one in fintech that exited in 2022 and one in healthcare that is running successfully with about 100 employees in the US and Germany. In her role as managing director at MindAhead, she strives to combine AI with personalized healthcare to combat the world’s increasing cognitive decline.

Axinesis
Pieter Van den Steen started his career as an environmental economist in researcher and consulting.
After his MBA at INSEAD he oriented his career on healthcare and has worked for the last 20 years in the medical devices industry with growing international responsibilities in commercial and general management functions. He joined big companies like J&J and Boston Scientific and worked for the last 7 years for start-ups of which nearly 4 years as CEO of Axinesis.

Professor of Paediatric Neurology, Royal Hospital for Children, Glasgow, UK; Board Member, European Paediatric Neurology Society; Board Member, European Brain Council
Sameer is Paediatric Neurologist at the Royal Hospital for Children and Honorary Professor, University of Glasgow. His interests include epilepsy, neurogenetics and innovation. He leads the Paediatric Neurosciences Research Group in the University of Glasgow and is clinical lead of the Scottish Genetic Epilepsy service. He is a Board Member & immediate past President of the European Paediatric Neurology Society (EPNS) and sits on the Board of the European Brain Council. Other roles have included Editor-in-Chief of the European Journal of Paediatric Neurology (2015-21 and Chair of the International League Against Epilepsy (ILAE) Commission on Classification & Terminology (2013-17). He co-designed vCreate Neuro, a smartphone video diagnosis and management web-application. Established in Glasgow in 2020 it is now used by >100 services in the UK and internationally.

Startup Scout & Project Officer, imec.istart
Maarten has worked very closely with early-stage digital health companies through his previous role as Regional Manager at BlueHealth Innovation Center, an early-stage Digital Health incubator in Belgium. Currently, he is the start-up scout at imec.istart, a leading tech accelerator for early-stage start-ups in Europe that has supported and invested more than 260 companies across the last 10 years.

Founder of Panakes, Diana has over 20 years of international experience in managing Venture Capital investment funds, through which she invested in over 60 start-ups across Europe. After several years of experience in the strategic consultancy sector at A.T. Kearney, Diana worked as Senior Advisor in the Investment Banking division of Lazard. In 2001 she co-founded 360 Capital Partners, a leading pan-European Venture Capital firm. She is a member of several national and international committees (EU and US) for the selection and promotion of innovative start-ups. She has also co-founded and chaired the International Venture Club, an association that brings together the main European venture capital firms. She is frequently involved as Scientific Advisor to Life Sciences conferences and acting in or chairing juries for the allocation of public funds at Italian, European and US level (i.e. Premio Marzotto, Life Star Awards, EIC H2020 and National Cancer Institute-SBIR initiative).

Convergence Partners
Daniel is the Co-Founder and Managing Partner at Convergence Partners, a European HealthTech venture capital firm that actively supports the internationalisation and business development of its portfolio companies in the world’s largest healthcare markets. Convergence currently focuses on investment opportunities in Behavioural Health and is in the process of launching a EUR 100m Brain Health Fund. Daniel has more than 15 years of High tech venture capital investing – and company building experience, focused on sectors that have a positive impact on planet and society. From 2009 to 2017, Daniel was Investment Partner and Investment Committee Member at Jadeberg Partners, a pioneering VC firm in European Cleantech-investing. Prior, Daniel worked for 7 years at Man Group, one of the world’s leading alternative investment management firms, in London, Chicago and Hong Kong, focused on environmental technology investments. Before joining Man Group, Daniel worked at the EU headquarters of Intel Corporation. Daniel holds an MBA and BSc in Business Studies from Bayes Business School, London (formerly Cass Business School) and is a Chartered Financial Analyst (CFA).

European Federation of Neurological Associations
Dr. Orla Galvin came to patient advocacy with a PhD in Medicine and background in drug discovery and design in both academic and industry environments. Transitioning to advocacy work at the umbrella patient organisation Retina International, Orla led high impact, multi-stakeholder socio-economic studies, patient preference studies, and accessibility studies across the globe assessing both rare and common conditions.
Orla is an internationally invited speaker to both research and clinical learned societies (for example EURORDIS, EU Retina, ERN-EYE), patient organisations, and industries on topics such as:
Patient and public involvement in advocacy, research and policy,
Research in advocacy and policy/evidence-based advocacy,
Education in advocacy,
Generation of real-world data,
Patient reported outcomes, and
Health economics.

CEO, E-Health Venture
Marius started his career at the Boston Consulting Group, and then set up the digital department of Proximus Luxembourg. Since 2019, he runs Belgium’s specialist health-tech incubator E-Health Venture, which brings together health & care incumbents to support innovative projects.